| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine-Metabolism Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry Rochester, New York 14642 Lilly Research Laboratories, Division of Eli Lilly and Company Indianapolis, Indiana 46285
Address all correspondence and requests for reprints to: John M.Amatruda, M.D., Department of Medicine, Endocrine-Metabolism Unit, University of Rochester, Rochester, New York 14642.
Methimazole was administered orally and rectally in a single dose of 60 mg to six euthyroid volunteers (three females and three males). Blood levels of methimazole were the same whether administered by the oral or rectal route, with peak levels of 1184 ± 118 and 1163 ± 150 (±SEM) ng/ml respectively.
This study provides evidence that the rectal administration of methimazole may be an alternative to treating hyperthyroid patients who are unable to take this drug by mouth.
* This work was supported in part by Grant RR-00044 from the Division of Research Resources, NIH.
Recipient of NIH Research Career Development Award AM-00366.
Received April 23, 1981.
This article has been cited by other articles:
![]() |
D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF] |
||||
![]() |
N. Stathatos and L. Wartofsky Thyrotoxic Storm J Intensive Care Med, January 1, 2002; 17(1): 1 - 7. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |